U.S. Stem Cell, Inc.U.S. Stem Cell, Inc.U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

No trades
See on Supercharts

USRM fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

U.S. Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product, MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
USRM has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company